Pharsight

Drugs that contain Brigatinib

1. List of Alunbrig drug patents

ALUNBRIG's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Apr, 2031

(8 years from now)

US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors
May, 2029

(6 years from now)

US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage

ALUNBRIG family patents

22

United States

9

Japan

5

Korea, Republic of

4

Israel

4

China

4

European Union

3

Mexico

3

Lithuania

3

Hungary

2

Denmark

2

Australia

2

Slovenia

2

Norway

2

Croatia

2

Portugal

2

Spain

EA

2

EA

2

Canada

1

South Africa

1

Hong Kong

1

Philippines

1

Costa Rica

1

Singapore

1

Colombia

1

Brazil

1

Cyprus

1

Netherlands

1

Peru

1

Poland

1

Dominican Republic

1

Chile

1

RS

1

Ecuador

1

Luxembourg

1

Ukraine

1

Tunisia

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic